LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $59.7143.

A number of analysts have weighed in on the stock. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Barclays raised their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st.

LivaNova Price Performance

Shares of LivaNova stock opened at $53.86 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The firm has a fifty day moving average price of $54.56 and a two-hundred day moving average price of $47.39. The company has a market cap of $2.94 billion, a PE ratio of -13.85 and a beta of 0.95.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. During the same period in the prior year, the firm earned $0.93 EPS. The business’s revenue was up 10.6% on a year-over-year basis. Analysts expect that LivaNova will post 2.85 EPS for the current year.

Hedge Funds Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently made changes to their positions in LIVN. Principal Financial Group Inc. lifted its holdings in shares of LivaNova by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 179,546 shares of the company’s stock worth $7,053,000 after acquiring an additional 3,668 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of LivaNova by 6.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company’s stock worth $1,840,000 after acquiring an additional 2,901 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of LivaNova by 2.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company’s stock worth $817,000 after purchasing an additional 500 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of LivaNova by 28.6% during the 1st quarter. New York State Common Retirement Fund now owns 48,290 shares of the company’s stock worth $1,897,000 after purchasing an additional 10,733 shares in the last quarter. Finally, CWM LLC increased its position in shares of LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after purchasing an additional 299 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.